Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$9.12
+3.2%		$7.85
$4.50
▼
$10.00
$192.48M2.3115,738 shs135,696 shs
Clene Inc. stock logo
CLNN
Clene
$4.11
+0.5%		$5.55
$3.88
▼
$13.50
$53.68M0.9683,907 shs73,354 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.90
+0.3%		$1.21
$0.88
▼
$1.94
$220.42M0.72628,204 shs1,482 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$6.24
+10.4%		$7.54
$2.80
▼
$8.97
$225.00M0.6337,931 shs2.50 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-3.05%-3.60%+0.82%+45.50%+1.54%
Clene Inc. stock logo
CLNN
Clene
-2.62%-6.41%-30.91%-40.72%-3.54%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+5.28%+26.33%+56.61%+45.77%+55.33%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+10.44%+1.30%-10.86%-12.97%-57.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$9.12
+3.2%		$7.85
$4.50
▼
$10.00
$192.48M2.3115,738 shs135,696 shs
Clene Inc. stock logo
CLNN
Clene
$4.11
+0.5%		$5.55
$3.88
▼
$13.50
$53.68M0.9683,907 shs73,354 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.90
+0.3%		$1.21
$0.88
▼
$1.94
$220.42M0.72628,204 shs1,482 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$6.24
+10.4%		$7.54
$2.80
▼
$8.97
$225.00M0.6337,931 shs2.50 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-3.05%-3.60%+0.82%+45.50%+1.54%
Clene Inc. stock logo
CLNN
Clene
-2.62%-6.41%-30.91%-40.72%-3.54%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+5.28%+26.33%+56.61%+45.77%+55.33%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+10.44%+1.30%-10.86%-12.97%-57.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$17.2589.06% Upside
Clene Inc. stock logo
CLNN
Clene
2.71
Moderate Buy$33.25708.61% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.33
Hold$9.50400.00% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLNN, CRDL, SBTX, and ACOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Clene Inc. stock logo
CLNN
Clene
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$18.00 ➝ $20.00
8/17/2026
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $10.00
8/14/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$17.00
7/30/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/15/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/14/2026
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/10/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$20.00
7/10/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$20.00
6/26/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$10.22M19.44N/AN/A$2.88 per share3.17
Clene Inc. stock logo
CLNN
Clene
$200K262.76N/AN/A($1.62) per share-2.54
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.11 per shareN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$20.67M-$1.10N/AN/AN/A-153.61%-54.60%-43.47%N/A
Clene Inc. stock logo
CLNN
Clene
-$26.17M-$3.50N/AN/AN/A-20,063.96%N/A-140.91%N/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$24.20M-$0.25N/AN/AN/AN/A-180.44%-140.28%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A

Latest CLNN, CRDL, SBTX, and ACOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Clene Inc. stock logo
CLNN
Clene
-$0.3680-$1.08-$0.7120-$1.08$0.06 million$0.09 million
8/13/2026Q2 2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.3921-$0.40-$0.0079-$0.40$4.38 million$6.00 million
8/13/2026Q2 2026
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.09-$0.04+$0.05-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
9.03
8.04
Clene Inc. stock logo
CLNN
Clene
N/A
1.94
1.93
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/A
5.55
5.55
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
Clene Inc. stock logo
CLNN
Clene
23.28%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
8.60%
Clene Inc. stock logo
CLNN
Clene
28.30%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A21.77 million19.90 millionN/A
Clene Inc. stock logo
CLNN
Clene
10012.78 million9.16 millionNo Data
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
20115.89 million109.80 millionNot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
October 17, 2024  |  pbs.orgP
10 Fun Facts About Mountain Gorillas
September 18, 2024  |  nationalgeographic.comN
CapstanTx secures $165 million to deliver precise in vivo cell engineering
July 28, 2024  |  pharmaphorum.comP
ARS Pharmaceuticals Inc (SPRY)
May 11, 2023  |  uk.investing.comhttps://uk.investing.com/equities/silverback-therapeutics-inc
Wild Isles
March 12, 2023  |  wwf.org.ukW
A look back at RNA Therapeutics – day one
February 23, 2023  |  pharmaphorum.comP
SPRY ARS Pharmaceuticals, Inc.
January 24, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/SPRY
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 22, 2022  |  247wallst.comhttps://247wallst.com/investing/2022/11/22/ars-pharma-ceo-richard-lowenthal-holds-8-silverback-stake-after-merger/
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 18, 2022  |  nasdaq.comhttps://www.nasdaq.com/articles/dr.-sarina-tanimoto-discloses-position-in-sbtx-silverback-therapeutics
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-announces-presentation-clinical-130000987.html?.tsrc=rss
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 8, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-closes-merger-silverback-210200048.html?.tsrc=rss
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
October 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silverback-fda-accepts-ars-pharm-s-nda-for-neffy-for-treatment-of-allergic-reactions-1031824142
FDA accepts ARS Pharma’s NDA for Neffy
October 24, 2022  |  thepharmaletter.comT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
October 23, 2022  |  kentuckytoday.comK
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/silverback-therapeutics-inc-announces-fda-113100379.html?.tsrc=rss
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
October 19, 2022  |  aaii.comA
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
October 12, 2022  |  bakersfield.comB
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 17, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/investigation-alert-halper-sadeh-llc-investigates-cvet-sbtx-irbt-1031746211
SBTX Silverback Therapeutics, Inc.
September 15, 2022  |  seekingalpha.comhttps://seekingalpha.com/symbol/SBTX/charting
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
September 6, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-notice-halper-sadeh-llp-investigates-ftai-sbtx-cvet-gbt-1031726462

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$9.12 +0.28 (+3.21%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Clene stock logo

Clene NASDAQ:CLNN

$4.11 +0.02 (+0.54%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.90 +0.01 (+0.26%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$6.24 +0.59 (+10.44%)
As of 08/17/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas